Article

STAAR ICL approved for market in China

Monrovia, CA-The People's Republic of China's State Food and Drug Administration (SFDA) granted approval to STAAR Surgical Co. to market its Visian implantable collamer lens (ICL) in China.

Monrovia, CA-The People's Republic of China's State Food and Drug Administration (SFDA) granted approval to STAAR Surgical Co. to market its Visian implantable collamer lens (ICL) in China.

"This approval is an important achievement for STAAR Surgical. It will allow us to enter a market that we believe has the potential to become one of the largest markets for the Visian ICL," said David Bailey, president and chief executive officer of STAAR Surgical. "Currently, China is the second-largest market in the world for the LASIK procedure and there is a higher rate of incidence for myopia and astigmatism in Asian countries compared with the rest of the world. With these two market dynamics, we believe that successful entry into this market could lead to meaningful growth in our overall refractive business."

Bailey added that a training center and regional distribution operation have been established, and was hopeful that the SFDA would approve Visian Toric ICL by the end of the year.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
© 2025 MJH Life Sciences

All rights reserved.